NRAS and hematopoietic and lymphoid cell neoplasm: Currently, they are no NRAS-mutant-specific drugs to treat hematological cancers because of the numerous challenges associated with this effort, while selective inhibitors of KRASG12V, KRASG12D, and KRASG12C mutants are already being tested in solid tumors [30].